加载中
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
收盘时
US$1.66
−US$0.06 · -3.49%
盘后
US$1.6315
−US$0.0285 · -1.72%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
日内区间
当前US$1.66
52周区间
当前US$1.66
盘中时间采用ET。市场数据可能有所延迟。
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
日内区间
当前US$1.66
52周区间
当前US$1.66
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 197.67万 USD | 1119.81万 USD | −285.08万 USD | 50万 USD | 1614.08万 USD |
| 销货成本 | 858.39万 USD | — | 1017.53万 USD | 855.69万 USD | 766.56万 USD |
| 毛利 | −660.72万 USD | 1119.81万 USD | −1302.61万 USD | −805.69万 USD | 847.53万 USD |
| 研究与开发 | — | 735.18万 USD | — | — | — |
| 销售、一般及管理费用 | 376.41万 USD | 500.14万 USD | 490.49万 USD | 406.25万 USD | 532.98万 USD |
| 营业费用 | 376.41万 USD | 1235.32万 USD | 490.49万 USD | 406.25万 USD | 532.98万 USD |
| 利息收入 | 74.41万 USD | 114.69万 USD | 136.69万 USD | 57.26万 USD | 6.77万 USD |
| 利息支出 | — | — | — | 2.71万 USD | 20.33万 USD |
| 折旧和摊销 | 6.08万 USD | 4.11万 USD | 2.87万 USD | 9453 USD | 380 USD |
| 营业利润 | −1037.14万 USD | −115.5万 USD | −1793.1万 USD | −1211.94万 USD | 314.55万 USD |
| 净利润 | −962.75万 USD | 8352 USD | −1635.21万 USD | −1075.86万 USD | −63.44万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI31.98万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF19.72万0.00%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS1.04万0.00%338.69亿 USD0.31%US$78.17-0.23%
Dimensional - US Sustainability Core 1 ETFDFSU8909.60.00%23.92亿 USD0.15%US$48.13+0.04%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR8799.520.00%455.91亿 USD0.17%US$84.43-0.01%
U.S. Micro Cap Portfolio ETFDFMC8668.80.00%75.58亿 USD0.43%US$57.70-0.20%
Dimensional - US Core Equity 2 ETFDFAC8242.240.00%885.96亿 USD0.21%US$45.31-0.04%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3708.320.00%61.81亿 USD0.26%US$68.32+0.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
